About Memphasys
Memphasys is a company based in Homebush (Australia) founded in 2006. Memphasys offers products and services including Felixâ„¢ System, Storage Medium, and Improved Medium. Memphasys operates in a competitive market with competitors including Cytoswim, Reproductive Solutions and ZyMot, among others.
- Headquarter Homebush, Australia
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website memphasys.com
- Social LinkedIn
- Legal Name Memphasys Limited.
- Annual Revenue$188.56 K (USD)7299.81as on Jun 30, 2026
- Net Profit-$2.82 M (USD)18.57as on Jun 30, 2026
- EBITDA-$2.45 M (USD)-4.11as on Jun 30, 2026
- Latest Funding Round$1.6M (USD), Post-IPO
Aug 2022
- Investors
Products & Services of Memphasys
Memphasys offers a comprehensive portfolio of products and services, including Felix™ System, Storage Medium, and Improved Medium.
Device for separating sperm from semen in IVF procedures.
Medium for long-term ambient storage of human sperm.
Medium for sperm isolation, fertilization, and cryopreservation.
Funding Insights of Memphasys
- Total Rounds 1
- Last Round Post-IPO — $1.6M
- First Round $1.6M
(Aug 2022)
- Investors Count 1
All 1 funding rounds of Memphasys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $1.6M | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Memphasys
Memphasys has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Peters Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global investment firm provides professional services for community improvement and international development. | 2004 | petersinvestmentgroup.com | Chicago, United States |
Investor details for Memphasys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Memphasys
4 people are tracked at Memphasys (1 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Alison Coutts | CEO | Leadership |
Robert Cooke | Non Executive Chairman | Board & advisors |
Andrew Goodall | Non Executive Director | Board & advisors |
Paul Wright | Non Executive Director | Board & advisors |
Complete people profiles for Memphasys
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Memphasys
Memphasys is a publicly listed company on the ASX with ticker symbol MEM in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 May 2007
- Listed onASX: MEM
- Listed entityMEMPHASYS LIMITED.
- Exchange sectorHealth technology
- ISINAU000000MEM5
- Share price0.01 AUD · 2026-10-09
- Market capitalisation15,476,168.00 AUD
- EPS (diluted, trailing year)-0.00 AUD
- Volume (last session)1,666
Financials of Memphasys
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | 273,790 AUD | -4.1M AUD | -3.6M AUD |
| 2025 | 3,700 AUD | -5.0M AUD | -3.4M AUD |
| 2024 | 60,000 AUD | -5.4M AUD | -4.5M AUD |
| 2023 | 15,370 AUD | -3.4M AUD | -3.0M AUD |
| 2022 | 27,150 AUD | -2.1M AUD | -2.6M AUD |
Detailed financial statements for Memphasys
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Memphasys
3 dated milestones of Memphasys across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Memphasys is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.6M.
Competitors of Memphasys
Memphasys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytoswim, Reproductive Solutions and ZyMot, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cytoswim.com | 2019 | Coventry, United Kingdom | $129,354 | 4 | Sperm selection tools for assisted reproduction are developed. | |
| rsifertility.com | 2017 | Dallas, United States | $300,000 | – | Developer of advanced sperm collection and processing technologies. It offers solutions for at-home semen analysis and in-clinic sperm processing, improving sperm quality and increasing the chances of successful conception. The company's products are designed to enhance sperm viability during collection, transport, and preparation for various fertility treatments, including IUI, IVF, and ICSI. These technologies aim to simplify the process for both patients and healthcare providers, improving outcomes and reducing stress. The company also provides support and resources for patients and clinics. | |
| zymotfertility.com | 2013 | Gaithersburg, United States | – | – | Develops innovative sperm separation devices for medical applications. |
Detailed competitors of Memphasys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Memphasys
The website of Memphasys (memphasys.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▲ 6.3% vs previous month
Latest news on Memphasys
Complete news archive for Memphasys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Memphasys
10 companies that operate in the same segment as Memphasys (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Memphasys
Memphasys was founded in 2006 and raised its 1st funding round 16 years after it was founded.
Memphasys is headquartered in Homebush, Australia. It is registered at Homebush, New South Wales, Australia.
Alison Coutts is the current CEO of Memphasys.
Annual revenue of Memphasys is $188.56K as on Jun 30, 2026.
Memphasys was founded in 2006 and is based in Homebush, Australia. Operations center on biotechnology for reproductive health, where an automated electrophoretic system called the Felix device is developed. This system separates sperm from raw semen, supporting assisted reproductive technologies. The companys work addresses challenges in fertility treatments through innovative cell separation methods.
Memphasys's top competitors include Cytoswim, Reproductive Solutions and ZyMot.
Memphasys offers Felixâ„¢ System, Storage Medium, and Improved Medium.
Yes, Memphasys is publicly traded on ASX under the ticker symbol MEM.
Memphasys has 1 investor. Key investors include Peters Investment Group.
Memphasys operates through Memphasys Ltd.